Mechanical Prevention of Distal Embolization During Primary Angioplasty: Safety, Feasibility, and Impact on Myocardial Reperfusion Ugo Limbruno, MD, PhD;

Slides:



Advertisements
Similar presentations
STEM-AMI OUTCOME TRIAL STem cElls Mobilization in Acute Myocardial Infarction Outcome Trial   A national, multicentre, randomised, open-label, Phase.
Advertisements

The EMERALD Trial Diabetic Substudy. EMERALD Diabetic Analysis To compare myocardial perfusion and infarct sizes in diabetic and non-diabetic patients.
Protection Devices in PCI-Treatment of Myocardial Infarction for Salvage of Endangered Myocardium Study Presented at American College of Cardiology Scientific.
Distal Protection: PRIDE, CAPTIVE Symbiot III, AiMI Dr James Cotton MD MRCP Heart and Lung Centre Wolverhampton.
Cyclosporine A reduces infarct size and has no detrimental effect of LV remodeling in STEMI patients Michel Ovize Cardiology Hospital and Inserm U886 Lyon.
Comparison of AngioJET Rheolytic Thrombectomy Before Direct Infarct Artery STENTing in Patients with Acute Myocardial Infarction: the JETSTENT trial David.
Comparison of AngioJET Rheolytic Thrombectomy Before Direct Infarct Artery STENTing in Patients with Acute Myocardial Infarction: the JETSTENT trial David.
University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.
The AiMI Trial Arshad Ali, MD, David Cox, MD, Nabil Dib, MD, Bruce Brodie, MD, Daniel Berman, MD, Navin Gupta, MD, Kevin Browne, MD, Robert Iwaoka, MD,
Francesco Liistro Cardiovascular Department, Arezzo, Italy Impact of Thrombus Aspiration on Myocardial Tissue Reperfusion and Left Ventricular Functional.
Proxis Proximal embolic protection in saphenous vein graft and infarct PCI Dan Blackman Leeds General Infirmary Advanced Angioplasty 2006.
Proximal Protection during Saphenous Vein Graft Intervention using the Proxis™ Embolic Protection System The PROXIMAL Trial Laura Mauri, MD, MSc, FACC,
Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty Study (ARMYDA-2) Trial ARMYDA-2 Trial Presented at The American College of Cardiology.
ATTEMPT study: pooled-Analysis of Trials on ThrombEctomy in acute Myocardial infarction based on individual PatienT data CLINICAL TRIAL UPDATE III ESC.
Is PCI necessary for AMI related artery with TIMI 3 flow ? Donghoon Choi Yonsei Cardiovascular Center Yonsei University College of Medicine.
Beyond TIMI 3 Flow CTFC < 14 CTFC > % (n=41) (n = 18/640) (n =35/563) 2.8% p= “TIMI 4” Flow TIMI 3 Flow 14 < CTFC < % % Risk of In Hospital.
The 90 Minute Wall: 60% Rates of TIMI Grade 3 Flow % TIMI 3 Flow.
Can we protect patients undergoing percutaneous coronary intervention better? Beneficial effects of short- and long-term trimetazidine MR therapy in patients.
Academic Medical Center Amsterdam Interventional Cardiology Koch TCT 2008 A Prospective Randomized Trial of Proximal Microcirculatory Protection in Patients.
Relationship of Ultrasound Plaque Characteristics to TMPG Following Intracoronary Stenting ↓ TMPG Post PCINo Δ or ↑ TMPGp-value Pre-PCI Plaque Area12.4.
A Prospective, Randomized Evaluation of Supersaturated Oxygen Therapy After Percutaneous Coronary Intervention in Acute Anterior Myocardial Infarction.
New strategies and perfusion/aspiration devices for primary PCI Sandra Garcia Cruset, PhD. Cordynamic B.U. Marketing Manager.
Trial Vignettes 1-3 Mark Mason Harefield Hospital Royal Brompton and Harefield NHS Trust.
MUSTELA : A Prospective, Randomized Trial of Thrombectomy vs. no Thrombectomy in Patients with ST-Segment Elevation Myocardial Infarction and Thrombus-Rich.
The MASTER Trial A Prospective, Randomized, Multicenter Evaluation of a PET Micronet Mesh Covered Stent (MGuard) in STEMI Sigmund Silber, MD, PhD FESC,
Thrombus aspiration versus conventional primary PCI in STEMI patients V. Mironov Russian Cardiology Research Center 2014.
↓ 30 d mortality ↓ Distal embolization ↑ Myocardial Blush 3 ↑TIMI 3 Post De Luca et al. EHJ 2008;29:
Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty Study (ARMYDA-2) Trial ARMYDA-2:ARMYDA-2:
Kirk N. Garratt, MD, FSCAI Welcome to the 11:40am Treatment of Thrombotic Lesions.
Randomized Early versus Late AbciXimab in Acute Myocardial Infarction treated with primary coronary intervention (RELAx-AMI Trial) Mauro Maioli M.D., Francesco.
Relationship of the TIMI Myocardial Perfusion Grades, Flow Grades, Frame Count, and Percutaneous Coronary Intervention to Long-Term Outcomes After Thrombolytic.
Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented at.
Randomized Early versus Late Abciximab in Acute Myocardial Infarction Treated With Primary Coronary Intervention (RELAx-AMI Trial) Mauro Maioli, MD, Francesco.
Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effectiveness of In-Laboratory High-Dose Clopidogrel.
M-Guard stent in STEMI patients with high thrombus burden lesions Mahmoud Shabestari Baktash Bayani Ali Eshraghi Bahram Shahri Mashhad University.
Total Occlusion Study of Canada (TOSCA-2) Trial
The European Society of Cardiology Presented by Dr. Saman Rasoul
Intra Coronary AdjunctivE Tenecteplase During Primary PCI for STEMI:
Presenter Disclosure Information
Impact of gender on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty L Grinfeld,
Circ Cardiovasc Interv
Presented by Dr. Leif Thuesen
ClinicalTrials.gov Identifier NCT
The American College of Cardiology Presented by Dr. Maurits T. Dirksen
European Heart Association Journal 2007 April
Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.
Late Breaking Clinical Trials
European Society of Cardiology 2003
Atorvastatin for Reduction of Myocardial Damage During Angioplasty
3-Year Clinical Outcomes From the RESOLUTE US Study
Impact of clopidogrel loading dose on the safety and effectiveness of bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction:
Published in the European Heart Journal
Myocardial Staining (TMPG 1)  Post-Stent in AMI
Secondary Efficacy Endpoints
Role of Stenting in Acute MI: PAMI Stent Pilot Trial
Elevated Admission Plasma Glucose Following ACS
Ischemic Postconditioning
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
Angioplasty Balloon-associated Coronary Debris and the EZ FilterWire
Dye strongly persistent
European Heart Journal Advance Access
DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.
Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial
INTRO AMI. INTEGRILIN AND. REDUCED DOSE. OF THROMBOLYTIC IN. ACUTE
Evolution of Myocardial Blush after MI
From Primary to Secondary Percutaneous Coronary Intervention: The Emerging Concept of Early Mechanical Reperfusion With Delayed Facilitated Stenting—When.
The American College of Cardiology Presented by Dr. A. Abazid
GUSTO 1 Trial 41,000 patients enrolled, landmark study
Craig R. Narins, MD, Karl A. Illig, MD  Journal of Vascular Surgery 
Presentation transcript:

Mechanical Prevention of Distal Embolization During Primary Angioplasty: Safety, Feasibility, and Impact on Myocardial Reperfusion Ugo Limbruno, MD, PhD; Andrea Micheli, MD; Marco De Carlo, MD; Giovanni Amoroso, MD, PhD; Roberta Rossini, MD; Caterina Palagi, MD, PhD; Vitantonio Di Bello, MD; Anna Sonia Petronio, MD; Gabriella Fontanini, MD; Mario Mariani, MD Circulation. 2003;108:171-176

FilterWire-Ex in Primary PCI 106 patients with acute MI undergoing primary PCI Matched Case-Control Study FilterWire-Ex (FW) A distal embolic protection device Successfully positioned in 89% of patients without complication (n = 53) Matched Control Matched for infarct-related artery, TIMI flow grade, gender and age (n = 53) Endpoints: Primary – Feasibility and safety of adjunctive FW use during primary PCI Secondary – Markers of effective reperfusion (ST resolution, myocardial blush grade, and cTFC); peak CK and CK-MB release, change in LVEF and WMSI at 30 days compared with admission; MACE (death, reinfarction, and need for target vessel revascularization) at 30 days Circulation 2003; 108:171-176

FilterWire-Ex in Primary PCI Corrected TIMI Frame Count p=0.005 Frames Circulation 2003; 108:171-176

FilterWire-Ex in Primary PCI Myocardial Blush Grade 3 p=0.006 Circulation 2003; 108:171-176

FilterWire-Ex in Primary PCI ST-segment Resolution p=0.006 Circulation 2003; 108:171-176

FilterWire-Ex in Primary PCI MACE at 30 Days p=0.488 Circulation 2003; 108:171-176